Composition and Persistence of Donor Cell Infiltrates in Host Target Organs Instigate the Development of Chronic Graft-Versus-Host Disease

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 3523-3523
Author(s):  
Antonia MS Mueller ◽  
Jessica A Allen ◽  
David Miklos ◽  
Karen Berry ◽  
Judith Shizuru

Abstract Chronic graft-versus-host disease (cGVHD) is the most common late complication after allogeneic hematopoietic cell transplantation (HCT). Its pathophysiology is poorly understood, a problem hampered by the scarcity of mouse models that accurately reproduce the human scenario. While acute (aGVHD) is characterized by donor T cell (doTC) infiltration damaging target tissues, cGVHD displays a wider range of alterations, often resulting in fibrosis with disrupted tissue architecture. Whether or not doTC drive this process versus (vs) other cell types has not yet been clarified. Indirect disruption of normal immunity caused by destruction of lymphoid tissues could contribute to the autoimmune-like syndrome. Here, we describe the progression of lymphocyte infiltrations of GVH targets post-HCT. Two MHC-matched, minor antigen-mismatched strain combinations were studied. Myeloablated BALB. B (H2b) and BALB/c (H2d) recipients were given FACS purified hematopoietic stem cells (HSC: c-Kit+Thy1.1loLin-Sca-1+) + 10^7 splenocytes (SP) from C57BL/6 (B6) (H2Db) or B10.D2 (H2d) donors, respectively. Mononuclear cells (MNC) from bone marrow (BM), spleen, lymph nodes (LN), thymus, peripheral blood, and liver were FACS analyzed for cell (sub-) type and chimerism 14, 28, 50 and 150 days (d) post-HCT. BALB.B recipients of B6 HSC + SP developed aGVHD with severe weight loss (>30%) and a mortality of 22%. Survivors never fully recovered baseline weight. Histologic changes shifted from defined infiltrates to disseminated disruptions of tissue structures. In contrast, BALB/c recipients showed sclerodermatous skin changes, but no mortality or other signs of systemic disease. In both strains the BM was markedly infiltrated with doTC during the acute phase: 14d post-HCT BALB.B BM consisted of ~50% mature doTC, and the majority (2/3) of these were CD8+ with an effector memory (EM) phenotype (<2% naïve CD8+). Tetramer staining revealed reactivity against the minor antigen H60 in 8–24% of CD8+ cells. The fraction of doTC decreased to ~20% of BM MNC on d28, and <5% by d50. CD4 and CD8 TC achieved a balanced ratio. While SP-derived doTC persisted long-term (d150) in the BM they were not H60 positive. B cells (BC) comprised only <3% of BM early post-HCT vs ~70% in recipients of pure HSCs. BC recovery was severely delayed (0.5–23% d50) and varied depending on the degree of GVHD. B10.D2 doTC infiltrates in the BM of BALB/c recipients (<42%) showed no preponderance of CD8 over CD4 TC. BC reconstitution was less impaired (up to 50% d28). By d50 TC numbers in the BM had normalized to <3%, and ~30% of cells were BC. Long-term follow up revealed no further abnormalities. Detectable doTC displayed equal proportions of naïve, central memory (CM) and EM phenotypes. The liver is a main target of B6 grafts in BALB.B recipients: 14d post-HCT Ficoll-Paqueisolated MNC contained 60–80% doTC, which were mostly EM CD8+ (80%), reactive to H60 in up to 30%. These subsets decreased over time, however, doTC infiltrates persisted beyond d150 (~30% of MNC). Infiltrating BCs were <2% early post-HCT vs ~15% in recipients of pure HSC. Of note, livers of the latter contained mainly Mac1Gr1+ cells and only modest amounts of doTC (<5%). BALB/c had less liver infiltrates on d14 and 28 (30–50%), and no prominence of CD8+. Instead, Mac1/Gr1+ cells predominated (30– 60%). 150 days post-HCT no difference was noted in lymphocyte distribution between normal controls, HSC recipients and those receiving SP grafts. Regarding other potential target organs, persisting mature doTC were notable in the thymuses of some B6 into BALB.B hosts. Generally, their proportion of immature double positive (DB) CD4/8 TC appeared decreased. Thymuses of B10.D2 into BALB/c recipients normalized completely by d150. Likewise their LN and spleen fully recovered by d50, with CD4>CD8 TC, naïve TC phenotypes exceeding EM, and ~40% BC. In conclusion, doTC infiltration of host organs is not inevitably associated with impairment of organ function and clinical disease. Nonspecific invasion of doTC likely occurs throughout the organism post-allogeneic HCT, and specific stimuli, such as minor antigens or cytokines are required to activate and perpetuate pathology. These data further suggest that characterizing the composition in the infiltrate in the acute setting may permit prediction of whether or not the initial infiltrates will lead to the fibrotic and sclerotic changes, the hallmarks of cGVHD.

2009 ◽  
Vol 1 (4) ◽  
pp. 147-152 ◽  
Author(s):  
Hiva Fassihi ◽  
Kamran Iqbal ◽  
Trish Garibaldinos ◽  
Robert Sarkany ◽  
Julia Scarisbrick ◽  
...  

Abstract Chronic graft-versus-host disease (GVHD) is a frequent complication after allogeneic hematopoietic stem cell transplantation (HSCT). Approximately 10% of patients with GVHD develop sclerodermatous changes, which can cause significant morbidity and are often refractory to standard systemic immunosuppression. We present two cases of sclerodermatous GVHD. The first is a 39-year-old man, who had a matched sibling, undergoing allogeneic HSCT for severe aplastic anemia. The second patient is a 7-year-old boy, who had an allogeneic HSCT from his HLA-identical mother for acute myeloid leukemia (AML). Both patients presented with widespread sclerotic changes, resulting in joint contractures and significant functional difficulties. Studies have shown UVA1 phototherapy to be a promising and well tolerated treatment modality in patients with sclerotic skin diseases. Both of our patients were treated with UVA1, which resulted in a significant skin softening, improvement in joint mobility and quality of life. UVA1 appears to be an effective treatment for refractory sclerodermatous GVHD; however, long-term clinical studies in larger groups are needed to accurately evaluate its efficacy and safety.


Blood ◽  
2000 ◽  
Vol 95 (12) ◽  
pp. 3683-3686 ◽  
Author(s):  
Samar Kulkarni ◽  
Ray Powles ◽  
Jennie Treleaven ◽  
Unell Riley ◽  
Seema Singhal ◽  
...  

Abstract Incidences of and risk factors for Streptococcus pneumoniaesepsis (SPS) after hematopoietic stem cell transplantation were analyzed in 1329 patients treated at a single center between 1973 and 1997. SPS developed in 31 patients a median of 10 months after transplantation (range, 3 to 187 months). The infection was fatal in 7 patients. The probability of SPS developing at 5 and 10 years was 4% and 6%, respectively. Age, sex, diagnosis, and graft versus host disease (GVHD) prophylaxis did not influence the development of SPS. Allogeneic transplantation (10-year probability, 7% vs 3% for nonallogeneic transplants; P = .03) and chronic GVHD (10-year probability, 14% vs 4%; P = .002) were associated with significantly higher risk for SPS. All the episodes of SPS were seen in patients who had undergone allograft or total body irradiation (TBI) (31 of 1202 vs 0 of 127;P = .07). Eight patients were taking regular penicillin prophylaxis at the time of SPS, whereas 23 were not taking any prophylaxis. None of the 7 patients with fatal infections was taking prophylaxis for Pneumococcus. Pneumococcal bacteremia was associated with higher incidences of mortality (6 of 15 vs 1 of 16;P = .04). We conclude that there is a significant long-term risk for pneumococcal infection in patients who have undergone allograft transplantation, especially those with chronic GVHD. Patients who have undergone autograft transplantation after TBI-containing regimens also appear to be at increased risk. These patients should receive lifelong pneumococcus prophylaxis. Consistent with increasing resistance to penicillin, penicillin prophylaxis does not universally prevent SPS, though it may protect against fatal infections. Further studies are required to determine the optimum prophylactic strategy in patients at risk.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 1337-1337
Author(s):  
Michael J Carlson ◽  
James M. Coghill ◽  
Michelle L. West ◽  
Angela Panoskaltsis-Mortari ◽  
Bruce R. Blazar ◽  
...  

Abstract Abstract 1337 Poster Board I-359 INTRODUCTION Graft-versus-host disease (GVHD) is a major complication following allogeneic bone marrow transplantation (BMT). Despite advances in understanding the etiology of GVHD it remains a formidable obstacle to the widespread application of BMT. A number of studies have demonstrated that T regulatory (Treg) cells represent a potential therapy for GVHD as Tregs have been shown to inhibit GVHD while preserving the beneficial graft-versus-leukemia (GVL) effect. Numerous groups, including our own, have demonstrated the importance of T cell migration in the pathology of GVHD. Following conditioning, donor T cells migrate to secondary lymphoid tissues. Once activated in the lymphatics, T cells migrate to GVHD target organs including; the skin, liver, lung and the gastrointestinal (GI) tract in response to the local production of chemokines. Disruption of chemokine-chemokine receptor interactions has been demonstrated to affect the pathology of GVHD. Previously, we have shown that Tregs lacking the chemokine receptor CCR5, which binds CCL3, CCL4, and CCL5, do not protect animals from lethal GVHD as well as WT Tregs, due to their impaired migration to the liver and lung. Thus, a greater understanding of the function of chemokine receptors on Tregs is important in deciphering how Tregs function and whether targeting these cells to lymphoid tissue or GVHD target organs would be preferable for treating patients in clinical trials. METHODS We utilized a parent into F1 haploidentical model to assess the role of CCR1 in Treg-mediated protection from GVHD. Here we demonstrate Tregs lacking CCR1, another receptor for CCL3 and CCL5, were unable to protect animals against lethal acute GVHD. While 67% of B6D2 recipients given 1×106 WT Tregs supplemented with 5×106 WT T cells and 3×106 B6 T cell-depleted BM cells survived, only 15% of the recipients given CCR1−/− Tregs survived (p < 0.03; Fisher's exact test). B6D2 recipient mice given WT Tregs had significantly reduced clinical scores for GVHD compared to B6D2 recipients of CCR1−/− Tregs (p <0.05) with elevated GVHD scores starting on day 28 post-transplant. Histopathology revealed significantly worse pathology in the liver (p < 0.03) and colon (p < 0.05) of CCR1−/− Treg recipients vs. WT Treg recipients. In vitro analysis demonstrated that CCR1−/− Tregs were capable of suppressing T cell responses to allo-antigen equally as well as WT Tregs, and CCR1−/− Tregs attained a normal activation phenotype. Interestingly, preliminary experiments suggested that CCR1−/− Tregs migrated to and/or expanded in GVHD target organs to a similar extent as WT Tregs. CONCLUSIONS Treg expression of CCR1 is required for the inhibition of GVHD. Tregs lacking CCR1 led to significantly more tissue destruction in the liver and colon, two predominant sites of GVHD pathology. Of interest, the migration of CCR1−/− Tregs to GVHD target organs and secondary lymphoid tissues did not appear to be compromised suggesting that CCR1 may be required for the function of Tregsin vivo. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2000 ◽  
Vol 95 (12) ◽  
pp. 3683-3686 ◽  
Author(s):  
Samar Kulkarni ◽  
Ray Powles ◽  
Jennie Treleaven ◽  
Unell Riley ◽  
Seema Singhal ◽  
...  

Incidences of and risk factors for Streptococcus pneumoniaesepsis (SPS) after hematopoietic stem cell transplantation were analyzed in 1329 patients treated at a single center between 1973 and 1997. SPS developed in 31 patients a median of 10 months after transplantation (range, 3 to 187 months). The infection was fatal in 7 patients. The probability of SPS developing at 5 and 10 years was 4% and 6%, respectively. Age, sex, diagnosis, and graft versus host disease (GVHD) prophylaxis did not influence the development of SPS. Allogeneic transplantation (10-year probability, 7% vs 3% for nonallogeneic transplants; P = .03) and chronic GVHD (10-year probability, 14% vs 4%; P = .002) were associated with significantly higher risk for SPS. All the episodes of SPS were seen in patients who had undergone allograft or total body irradiation (TBI) (31 of 1202 vs 0 of 127;P = .07). Eight patients were taking regular penicillin prophylaxis at the time of SPS, whereas 23 were not taking any prophylaxis. None of the 7 patients with fatal infections was taking prophylaxis for Pneumococcus. Pneumococcal bacteremia was associated with higher incidences of mortality (6 of 15 vs 1 of 16;P = .04). We conclude that there is a significant long-term risk for pneumococcal infection in patients who have undergone allograft transplantation, especially those with chronic GVHD. Patients who have undergone autograft transplantation after TBI-containing regimens also appear to be at increased risk. These patients should receive lifelong pneumococcus prophylaxis. Consistent with increasing resistance to penicillin, penicillin prophylaxis does not universally prevent SPS, though it may protect against fatal infections. Further studies are required to determine the optimum prophylactic strategy in patients at risk.


Blood ◽  
2008 ◽  
Vol 111 (10) ◽  
pp. 5242-5251 ◽  
Author(s):  
Britt E. Anderson ◽  
Patricia A. Taylor ◽  
Jennifer M. McNiff ◽  
Dhanpat Jain ◽  
Anthony J. Demetris ◽  
...  

Abstract Graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality in allogeneic stem cell transplantation. Effector memory T cells (TEM) do not cause GVHD but engraft and mount immune responses, including graft-versus-tumor effects. One potential explanation for the inability of TEM to cause GVHD is that TEM lack CD62L and CCR7, which are instrumental in directing naive T cells (TN) to lymph nodes (LN) and Peyer patches (PP), putative sites of GVHD initiation. Thus TEM should be relatively excluded from LN and PP, possibly explaining their inability to cause GVHD. We tested this hypothesis using T cells deficient in CD62L or CCR7, transplant recipients lacking PNAd ligands for CD62L, and recipients without LN and PP or LN, PP, and spleen. Surprisingly, CD62L and CCR7 were not required for TN-mediated GVHD. Moreover, in multiple strain pairings, GVHD developed in recipients that lacked LN and PP. Mild GVHD could even be induced in mice lacking all major secondary lymphoid tissues (SLT). Conversely, enforced constitutive expression of CD62L on TEM did not endow them with the ability to cause GVHD. Taken together, these data argue against the hypothesis that TEM fail to induce GVHD because of inefficient trafficking to LN and PP.


Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 4703-4703
Author(s):  
Cesar H Gutiérrez-Aguirre ◽  
Juan A. Flores-Jiménez ◽  
Olga Cantú-Rodríguez ◽  
Jorge Cuervo-Sierra ◽  
Adrián A. Ceballos-López ◽  
...  

Abstract Abstract 4703 Background: Chronic graft-versus-host disease (cGVHD) is a common late complication of allogeneic hematopoietic stem cell transplantation. Corticosteroids are the standard initial treatment for cGVHD. A second-line treatment is not well defined. We prospectively evaluated the effectiveness and safety of low doses of alemtuzumab and low doses of rituximab as treatment steroid-refractory cGVHD. Materials and Methods: Ten men and 5 women with cGVHD refractory to steroids and CSA were included. All patients received subcutaneous Alemtuzumab 10 mg/day/3 days and intravenous Rituximab 100 mg on days +1, +7, +14 and +21. Results: The median age was 41 years. The main organ involved were oral mucosa (86.7%), eyes (66.7%), liver (60%), skin (53%), lungs (13.3%) and intestinal tract (6.7%). The overall response was 100% at 30-day evaluation; 10 patients (67%) had partial remission (PR), and 5 patients (33%) had complete remission (CR). At 90-day evaluation, 7 (50%) patients had PR, 4 (28%) had CR; three (21%) relapsed and 1 patient not reached evaluation. Currently, 5 patients have reached the 365-day follow-up evaluation, 2 (40%) had PR, 2 had CR and 1 showed progression. The adverse effects were mainly infectious and one patient died from pneumonia. Conclusion: This combination therapy appears to be an efficacious and safe as treatment for steroid-refractory cGVHD. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2009 ◽  
Vol 113 (15) ◽  
pp. 3620-3630 ◽  
Author(s):  
Matin M. Imanguli ◽  
William D. Swaim ◽  
Stacy C. League ◽  
Ronald E. Gress ◽  
Steven Z. Pavletic ◽  
...  

Abstract Although chronic graft-versus-host disease (cGVHD) is a major long-term complication of allogeneic hematopoietic stem cell transplantation, little is known of its pathogenesis. We have systematically examined oral mucosa among cGVHD patients and determined that the clinical severity of oral cGVHD was correlated with apoptotic epithelial cells, often found adjacent to infiltrating effector-memory T cells expressing markers of cytotoxicity and type I cytokine polarization. Accumulation of T-bet+ T-cell effectors was associated with both increased proliferation and the expression of the type I chemokine receptor CXCR3. Concurrently, in both infiltrating cells and keratinocytes, we observed increased expression of the CXCR3 ligand MIG (CXCL9) and interleukin-15 (IL-15), type I interferon (IFN)–inducible factors that support the migration, type I differentiation, and expansion of alloreactive effectors. In severely affected mucosa, we observed high levels of MxA, a protein specifically induced by type I IFN, and signal transducer and activator of transcription 1 (STAT1) phosphorylation, a critical step in the IFN-signaling pathway, along with increased numbers of plasmacytoid dendritic cells. These data challenge the current paradigm of cGVHD as a type II cytokine–driven disorder and support the model that oral cGVHD results from type I IFN–driven immigration, proliferation, and differentiation of T-bet+ type I T effectors. The clinical trials are registered at http://www.clinicaltrials.gov as NCT00331968.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 516-516
Author(s):  
Zachariah A. McIver ◽  
Andrew Grim ◽  
Nicolas Naguib ◽  
A. John Barrett

Abstract Abstract 516 Early lymphocyte recovery is an important determinant of hematopoietic stem cell transplant (SCT) outcome. We found that robust day 30 lymphocyte counts are associated with a decreased incidence of relapse, decreased rates of both acute and chronic graft-versus-host disease (a-GvHD, c-GvHD), and increased survival. Natural killer (NK) cells contribute to lymphocyte recovery and may be associated with a strong graft-versus-leukemia and anti-GvHD effect. However, the contribution of the recovery of specific T cell subsets to transplant outcome has not been fully explored. We studied 43 patients undergoing a myeloablative matched-sibling T-cell depleted or selectively depleted SCT for a variety of hematological malignancies including AML, ALL, CML, and MDS. Median age was 43 years (range, 13–68), and median CD34 cell dose was 6.1×106/kg (range, 3.1-10.1). Thirty-one patients developed a-GvHD (12 grade I, 18 grade II, 1 grade II). Twelve patients had c-GvHD (7 limited, 5 extensive). On day 30 after SCT a peripheral blood sample was collected on all patients and cryopreserved. In preparation for analysis, mononuclear cells from these samples were thawed and rested overnight. Flow cytometry was then performed on a BD FACS CantoII flow cytometer with multicolor fluorochrome antibodies to CD3, CD4, CD8, CD27, and CD45RO. Subsets were defined as follows: Naive (N) CD27+CD45RO-, Central Memory (CM) CD27+CD45RO+, Effector Memory (EM) CD27-CD45RO+, and Effectors (E) CD27-CD45RO-. Data was analyzed by BD FACSDiva software, and Kaplan-Meier survival statistical analysis was performed on the readouts. Median subset frequencies were CD3+: 254 /μL (range, 75-2085), CD4+ : 132 /μL (range, 3-501), CD8+ :101 /μL (range, 9-1361), CD4+ EM 49/μL (range, 2-252), CD4+CM 60/μL (range, 1-253), CD8+ EM: 50 cells/μL (range 2-977), CD8+ CM 28 /μL (range, 2-401), Naïve and Effector cells were minimally or non-detected in both CD4+ and CD8+ compartments. When T cell subset recovery was correlated with transplant outcomes (a-GVHD, c-GVHD, relapse and survival) one significant association was identified: low CD4+ CM counts correlated with a higher incidence of c-GvHD. Patients that had less than the median value of 60 CD4+ CM cells/μL had a significantly higher likelihood of developing c-GvHD (HR 4.28, p=0.039, see figure). Additionally, when considering degree of disease, low CD4+ CM counts were associated with the severest manifestations of c-GvHD (p=0.021). As a result, we conclude that low absolute concentrations of CD4+ CM cells on day 30 after SCT reflects a deficiency in regulatory mechanisms important in the control of alloreactivity, and may be used as a surrogate marker for individuals at risk of developing c-GvHD. Disclosures: No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document